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Abstract
Background: Type 2 diabetes is an important risk factor for the development of coronary artery disease (CAD).
Focal or diffuse inflammation is often present in the vessels of patients with CAD. Mast cells are frequently present
in the plaques as well as in the inflammatory infiltrates in the atherosclerotic vessel wall. In the study we wanted
to examine whether there are differences in the morphology, number and distribution of mast cells and in their
ability to modify the atherosclerotic process in coronary arteries (CA) in the diabetic vs. the hypertensive
population of patients with CAD.
Methods: Coronary artery endarterectomy specimens were obtained from patients with diabetes or hypertension
as the only risk factor for CAD. The specimens were stained with haematoxylin-eosin and Sulphated Alcian Blue for
mast cells and with immunofluorescent methods for fibrinogen-fibrin and IgG deposits in the vessel wall. Both
morphological and stereological assessments were conducted for mast cells and mononuclear cell infiltrates.
Results: The histological analysis of the vessel wall of diabetic patients in comparison with hypertensive patients
showed a damaged endothelial cells layer and deposits of fibrin-fibrinogen and IgG in the tunica intima and
media. The stereological count revealed a diminished numerical density of mast cells and a significantly higher
volume density of the mononuclear cells. Mast cells displayed cytoplasmic vacuolization, extracellular extrusion of
granule and pyknotic nuclei.
Conclusion: This preliminary study suggests that the impaired mast cells might be the reason for more extensive
inflammatory and immunologic atherosclerotic changes in the CA vessel wall of CAD patients with type 2 diabetes.
Trial registration: 134/88;C3-0564-381-92
Background
Coronary artery disease (CAD) can be macroscopically
visible as one or more localized atherosclerotic plaques,
or as a diffuse, long, concentric thickness of the vessel
wall, which protrudes and obstructs the vessel lumen.
These changes alter the structure of the vessel wall, ulti-
mately disrupting normal cardiac function. CAD is
defined as a chronic inflammatory disease, and several
cytokines and growth factors are involved in the patho-
genesis of the disease [1-6]. Surgical procedures on
coronary arteries (endarterectomy) enable the perfor-
mance of morphologic and morphometric analyses of
atherosclerotic changes of the coronary arteries. Impor-
tant risk factors for the development of CAD are type 2
diabetes and arterial hypertension. Atherosclerosis is
now generally accepted as a chronic inflammatory con-
dition and there is also growing evidence of an impor-
tant role of chronic inflammation in type 2 diabetes [7].
The differences in the content and recruitment [8] of
various inflammatory cells [9] and their autocrine and
paracrine secretory activities have been reported to influ-
ence the fate of the atherosclerotic plaque. Among the
inflammatory cells, mast cells are obligatory accompany-
ing elements of the localized and diffuse inflammatory
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years, several investigations have shown that the largest
density of mast cells is located in the atherosclerotic pla-
que of the vessel wall, both in early and advanced CAD,
especially in the shoulder region of unstable plaques
[10-12]. Mast cells play a crucial role in the inflammatory
process [13,14]via many secretory mediators [15], in the
activation of other inflammatory cells (e.g. lymphocytes,
T macrophages and foam cells) and in influencing the
metabolism and the circulation of HDL and LDL lipopro-
teins. Proteoglycans and proteases derived from activated
mast cells play an important role in the regulation of coa-
gulation and fibrinolysis, processes that are closely con-
nected with the development and complications of the
atherosclerotic process. The release of heparin as an
anticoagulant substance from the mast cells, which leads
to higher endogenous heparin levels and higher levels of
IgE, may have the primary role in the protective function
of vessel wall endothelial cells and act to reduce the com-
plications of CAD [16]. It was reported that [17] mast
cells may influence the course of the atherosclerotic pro-
cess by releasing cytokines from their secretory granules
and by coordinating the transportation of inflammatory
cells in the vessel wall.
We hypothesized that the morphology, number, distri-
bution and probably the function of mast cells may dif-
fer in CAD patients with type 2 diabetes or arterial
hypertension, as the only risk factor. Thus, we examined
endarterectomy specimens of CA from CAD patients
with diabetes or with arterial hypertension using histolo-
gical and histomorphometrical analyses (a stereological
count with the volume density of the mononuclear infil-
trates, and the numeric density of mast cells).
Methods
Coronary endarectomy sequesters were obtained during
Coronary Artery Bypass Graft Surgery (CABG) at the
University Clinic of Cardiovascular Surgery, Novi Sad,
Serbia, from 20 patients with CAD. The study was
approved by the National Medical Ethics Committee. In
20 patients with CAD CABG surgery was performed
due to angina pectoris, whereas endarectomy was per-
formed in those coronary arteries with diffuse stenotic
lesions. Twenty consecutive patients with diffuse CAD
were enrolled in the study with either type 2 diabetes or
arterial hypertension. The exclusion criteria were type 1
diabetes and the presence of both disorders (arterial
hypertension and type 2 diabetes). Patients were divided
in two groups the group of patients with type 2 diabetes
only (N = 10) and the group of patients with arterial
hypertension only (N = 10) (Table 1). The diabetic
patients had been treated for 9.5 ± 1.716 years, the
hypertensive patients for 7.5 ± 1.080 years. After
informed consent was obtained from the patients, a
detailed interview was made. Patients were classified as
having type 2 diabetes according to the current Ameri-
can Diabetes Association criteria for the diagnosis and
classification of diabetes [18]. The body mass index
(BMI) was calculated as weight in kilograms divided by
height in square meters. Total cholesterol, low density
lipoproteins (LDL), high density lipoproteins (HDL) and
triglycerides were determined by standard biochemical
methods. Cigarette smoking was defined as a binary
variable.
Endarterectomy specimens were surgically taken from
the left anterior descendent coronary artery, the left cir-
cumflex coronary artery, or the right coronary artery.
The tissue samples were formaldehyde fixed, embedded
in paraffin and cut into 5 μm thick serial sections. The
standard haematoxylin-eosin staining method for the
vessel wall tissue and the Sulphated Alcian Blue method
for the demonstration of intracellular or extracellular
localization of mast cell granules were used. Immuno-
fluorescent methods were performed to show fibrino-
gen-fibrin and IgG deposits in the endarterectomy
specimens as described previously [19]. The number of
mast cells and mononuclear cells were counted in 20
random high power fields (× 400). The numerical den-
sity of the mast cells and the volume density of the
mononuclear cells infiltrates were calculated using pre-
viously described stereologic methods [20,21]. Histologi-
cal, immunofluorescent and stereological analyses were
performed in step serial sections. Degranulated mast
cells were defined as cells with > 50% of cytoplasmic
granules extruded extracellular in the vicinity of the cell
body (Figure 1). Their presence was noted in 20 random
high power fields (× 1000 magnification) [22]. Numeri-
cal data are reported as a mean value ± SD. The stereo-
logical results for mast cells and mononuclear cells
infiltrates for diabetic and non diabetic patients were
Table 1 Clinical data about diabetic and hypertensive
groups of patients
Characteristics Diabetic
group
Hypertensive
group
P value
Number 10 10
Age (years) 56.6 ± 7.58 60 ± 6.16 0.274
BMI (kg/m
2) 28.08 ± 2.44 27.6 ± 3.37 0.72
Systolic pressure (mmHg) 126.5 ± 6.26 174.5 ± 17.07 < 0.001
Diastolic pressure
(mmHg)
79.5 ± 5.50 113.4 ± 10.80 < 0.001
Glucose level (mmol/l) 7.54 ± 1.61 4.64 ± 0.82 < 0.001
Total cholesterol (mmol/l) 6.52 ± 1.57 5.82 ± 1.56 0.331
HDL cholesterol (mmol/l) 1.04 ± 0.04 1.25 ± 0.45 0.037
LDL cholesterol (mmol/l) 3.26 ± 1.43 3.85 ± 1.68 0.41
Triglycerides (mmol/l) 2.35 ± 0.76 1.78 ± 0.6 0.856
Cigarette smoking 2 (20%) 3 (30%) 0.65
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considered as statistically significant. A statistical analy-
sis was performed using the Excel program, Microsoft
Office 2003.
Results
The clinical data of patients with type 2 diabetes and
arterial hypertension are shown in Table 1. Patients had
no statistically significant difference in BMI, total cho-
lesterol, LDL cholesterol and triglycerides, and in the
incidence of cigarette smoking, whereas the difference
in the HDL cholesterol level was of borderline signifi-
cance. Due to different inclusion criteria, they differ in
blood pressure and glucose level (Table 1).
Moreover, they did not differ in the frequency of lipid-
lowering drugs, beta blockers, ACE inhibitors and anti-
platelet drugs.
In diabetic patients, a histological analysis revealed a
focal or diffuse mononuclear cells infiltration, the pre-
sence of fibrin-fibrinogen and IgG deposits in the tunica
intima and tunica media of the endarterectomized cor-
onary vessels. In hypertensive patients, fibrin-fibrinogen
as well as IgG deposits were absent, and mononuclear
infiltrates were rarely observed. In CAD patients with
type 2 diabetes, damaged endothelial cells and large
areas of luminal boundaries without endothelium with
denuded intimal layers were found. In CAD patients
with arterial hypertension only, continuous endothelial
cell layers were demonstrated.
The morphological analysis of mast cells showed that
the nuclear pyknosis, vacuolization and degranulation of
mast cells were more intense in diabetic patients in com-
parison with hypertensive patients. Morphometric analy-
sis demonstrated a significantly higher volume density
(Vv) of mononuclear cells infiltrates in diabetic patients
in comparison with hypertensive patients (Figure 2).
Moreover, a lower numerical density of mast cells (Nvm)
was demonstrated in diabetic patients in comparison
with non-diabetic patients with arterial hypertension
(Figure 3).
Discussion
In this preliminary study we demonstrated a clear differ-
ence in atherosclerotic lesions in CAD patients with
type 2 diabetes in comparison with the patients from
the hypertensive group. The samples from diabetic
Figure 1 Degranulated mast cells with picnotic nucleus (bar =
20 μm).
0
0,02
0,04
0,06
0,08
0,1
0,12
Diabetic group Hypertensive group
V
v
 
(
m
m
3
/
m
m
3
)
*
Figure 2 Volume density (Vv) of mononuclear cells infiltrates in diabetics in comparison with hypertensive patients.* P < 0.05.
Pleskovič et al. Cardiovascular Diabetology 2011, 10:40
http://www.cardiab.com/content/10/1/40
Page 3 of 5patients showed a greater degree of inflammation com-
pared to the samples of hypertensive patients. The
fibrin-fibrinogen and IgG deposits, accompanying abun-
dant mononuclear cells infiltrates, and damaged
endothelial cells of coronary arteries may indicate that
atherosclerosis in diabetic patients constitutes humoral
[23] and cellular immune responses [24,25]. We postu-
late that normal mast cells play an important role in the
protection of the integrity of endothelial cell layers and
the vessel wall, probably via their paracrine activity,
especially through the release of heparin. It is known
that in hyperglycemic conditions heparin may protect
cells from injury [26]. In diabetic patients, the nuclear
pyknosis, degranulation and vacuolization of the mast
cells in the CA indicate that they are damaged. There-
fore, their protective role of the vessel wall may be
diminished. Their impairment, lower numeric density,
nuclear pyknosis, degranulation and vacuolization of the
mast cells in diabetic patients might be the reasons for
more extensive inflammatory and immunologic athero-
sclerotic changes observed in diabetic CAD patients in
comparison with hypertensive CAD patients. The lower
number of impaired mast cells cannot coordinate the
normal transportation of mononuclear cells through the
vessel wall. Inflammatory cells, fibrin-fibrinogen and IgG
deposits accumulate in the vessel wall as atherosclerotic
plaques that protrude and occlude vessel lumen. In con-
trast, in hypertensive CAD patients, the morphology of
mast cells was normal and the inflammatory changes
were less intense. Fibrin-fibrinogen and IgG deposits
accumulations were absent. A diminished numerical
density of impaired mast cells and a significantly higher
number of mononuclear cells infiltrates in the athero-
sclerotic plaques of CA vessel wall indicate differential
inflammatory processes within the CA vessel wall in dia-
betic patients vs. hypertensive patients.
A major limitation of this preliminary study is the
relatively low number of CAD cases with either type 2
diabetes or arterial hypertension. We are planning to
enroll new CAD cases with either type 2 diabetes or
arterial hypertension to increase the reliability of the
study. However, there are only some patients with CAD
suitable for the endarterectomy procedure. Further stu-
dies enrolling larger numbers of CAD are needed to
confirm our findings.
Conclusion
This preliminary study suggests that the impaired mast
cells might be the reason for more extensive inflamma-
tory and immunologic atherosclerotic changes in the
CA vessel wall of CAD patients with type 2 diabetes.
Moreover, we speculate that mast cells are differently
involved in atherosclerotic lesions in CAD patients with
type 2 diabetes in comparison with hypertensive
patients.
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Figure 3 Numerical density of mast cells (Nvm) in diabetic group in comparison with hypertensive group of patients.*P < 0.05.
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